source
- Merck’s TROP2 ADC extends survival in pivotal gastroesophageal cancer trialMerck & Co.’s sacituzumab tirumotecan has improved overall survival in a phase 3 cancer trial, delivering a second pivotal global victory for the TROP2-directed antibody-drug conjugate.
- Ridley Block Operations recalls Crystalyx HE-20% batch over dangerous urea nitrogen levels in cattle feedRidley Block Operations announced a voluntary recall of one lot of its Crystalyx HE-20% feed after testing revealed elevated non‑protein nitrogen from urea, a condition that can be lethal to cattle…